Positive Phase III results have been released for first- and second-line CLL treatment with Rituxan.

Rituxan is the most successful targeted therapy drug to date, having long been established as a standard in non-Hodgkin’s lymphoma treatment. Regulatory approval in chronic lymphocytic leukemia will further drive the drug’s sales potential. According to the report "Stakeholder Opinions: Non-Hodgkin’s Lymphoma - Is there room to emulate Rituxan’s success?" of independent market analyst Datamonitor sales growth may be hindered in some markets due to Rituxan’s existing off-label use.
(more…)

With 2009 nearly upon us, look for new product marketers to make the year interesting with beauty foods and drinks, detox products and concentrated liquid cleaners that cut costs and help the environment. Datamonitor’s Product Launch Analytics takes a look at these and other trends in consumer packaged goods for the coming year.
(more…)

Global Markets Direct: Nuclear Power is back at the top of the agenda for governments and corporates alike.

‘The Reemergence of the Nuclear Industry in the Global Energy Sector’, a new report from Global Markets Direct, the leading business information provider, gives an in-depth analysis on various aspects of nuclear energy industry and also provides insights into its potential expansion in the years ahead.
(more…)

Cytotoxic therapy, or chemotherapy as it is commonly known, has been the cornerstone of cancer treatment for many years and involves the use of drugs that are toxic to all cells – including those that are perfectly healthy. Whilst relatively effective, this leads to the unpleasant side effects commonly associated with cytotoxic treatment, such as vomiting, nausea, alopecia and fatigue. Despite this, and the rise in prominence of targeted therapies, cytotoxics are used in almost all cancer types and as a result of this high volume of sales, make up the second largest selling class of cancer therapeutics. However, given the relative maturity of this therapeutic class, generics companies remain keen to emulate the success of several cytotoxic brands that have attained blockbuster sales (more than $1 billion) over the years, and according to the report "Cytotoxic Therapy Cancer Brands - Looming patent expiries limit market growth" of independent market analyst Datamonitor*, generic incursion will cause a decline in total cytotoxic market value after it reaches a peak of $16.5bn** in 2013.
 
(more…)